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starting point for broad-spectrum protease
inhibitors against dengue and chikungunya virus†
Soumendranath Bhakat,*a Leen Delang,b Suzanne Kaptein,b Johan Neyts,*b
Pieter Leyssenb and Venkatesan Jayaprakash*c
Drug repurposing or re-proﬁling has become an eﬀective strategy to identify novel indications for
already-approved drugs. In this study, peptidomimetic FDA-approved HIV/HCV inhibitors were
explored for their potential to be repurposed for the inhibition of the replication of dengue (DENV)
and chikungunya virus (CHIKV) by targeting the NS2B-NS3 and NSP2 protease, respectively.
MM/GBSA-based binding free energy results put nelﬁnavir forward as a potential inhibitor of both
dengue and chikungunya virus, which subsequently was further explored in a virus-cell-based assay
for both viruses. Nelﬁnavir showed modest antiviral activity against CHIKV (EC50 ¼ 14  1 mM and
a selectivity index of 1.6) and was slightly more active against DENV-2 (EC50 ¼ 3.5  0.4 mM and
a selectivity index of 4.6). Even though the antiviral potency was limited, the fact that some activity
was observed in these assays made it worthwhile exploring the potential and properties of nelﬁnavir as
a stepping-stone compound: a more detailed computational analysis was performed to understand
the binding mode, interaction, hydrogen bond distance, occupancy and minimum pharmacophoric
features. The comprehensive data set that resulted from these analyses may prove to be useful for the
development of novel DENV and CHIKV protease inhibitors.1. Introduction
The discovery and development of novel chemical entities from
scratch into a drug for clinical use is a time- and money-
consuming task.1–3 Therefore, there is a lot of truth in the
famous quote by Nobel laureate James Black: “The most fruitful
basis of the discovery of a new drug is to start with an old drug”.1
Taking these words to heart, there is still a lot of potential in the
many compounds that are currently on the market and for
which it is still unknown how they exactly elicit their benecial
eﬀects. Furthermore, even for drugs with a known mechanism,
it still makes sense to explore their versatility. Antiviral drug
development for neglected tropical diseases is considered to be
challenging because of the low market value, in spite of the
increasing need.4–6 Drug repositioning or re-proling7–10 may be
an attractive and eﬀective process to unlock the clinical
potential of established molecules for the treatment ofniversity, P.O. Box 124, SE-22100 Lund,
c.lu.se
nt of Microbiology and Immunology, Rega
of Virology and Chemotherapy, B-3000
.kuleuven.be
Technology, Birla Institute of Technology,
bitmesra.ac.in
tion (ESI) available. See DOI:
49neglected tropical diseases such as dengue (DENV) and chi-
kungunya virus (CHIKV).11–14
Dengue and chikungunya virus are the two most prevalent
tropical mosquito-borne diseases that aﬀect humans15,16. Cases
have even been reported on the concurrent transmission of
both viruses amongst travelers.15DENV (genus Flavivirus, family
Flaviviridae) is endemic in more than 100 countries with an
average annual global incidence of 390 million cases, of which
around 96 million develop dengue disease (Bhatt et al., 2013
(ref. 17)). In general, DENV infection follows a subclinical
course that is characterized by non-specic symptoms.
However, a second infection with any of the other four DENV
serotypes is strongly correlated with the clinically more severe
dengue hemorrhagic fever (DHF) and dengue shock syndrome
(DSS).18,19 Various vaccine development programs are already
ongoing for several years,20,21 but this proves to be quite chal-
lenging due to the link between secondary infection and the
underlying mechanism of DHF/DSS, i.e. antibody-dependent
enhancement of infection. Patients those who suﬀer from
DENV disease can only be oﬀered symptomatic treatment and
intensive care.18 CHIKV belongs to the Alphavirus genus of the
Togaviridae family.22,23 This viral infection is mostly character-
ized by acute and chronic articular manifestations. Although
CHIKV infection is rarely fatal, the disease evolves into
a chronic stage in 50% of the infected patients and is char-
acterized by persistent disabling polyarthritis that can severelyThis journal is © The Royal Society of Chemistry 2015
Fig. 1 (a) The active site region of the DENV NS2B-NS3 protease is delineated in red. (b) The catalytic triad of the DENV NS2B-NS3 protease
consists of His51 (B), Asp75 (A) and Ser135 (C). The ligand-bound closed conformation of the dengueNS2B-NS3 protease (PDB: 3U1I) was used to
fathom the position of the active site and catalytic triad.
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View Article Onlineincapacitate the patient for weeks up to several years beyond the
acute stage.24 Despite its wide spread and high morbidity, at the
moment, there is no approved vaccine or antiviral treatment
available.22 The administration of analgesics, antipyretics, and
anti-inammatory agents is the only way to increase the comfort
of the patient.
For viruses, the non-structural (NS) viral proteins are
attractive targets for the design of drug-like molecules.15 A lot of
information, like the crystal structure, is available for proteases,
which, for other viruses, has already proven to facilitate the
development of peptidomimetic inhibitors. The hydrophobic
NS2B part is essential for the activation of the DENV NS3, which
contains the catalytic triad His51, Asp75 and Ser135 within its
N-terminal region (Fig. 1). For CHIKV, NSP2 (Fig. 2), which
carries three catalytic cysteine residues (Cys1233, Cys1274 andFig. 2 The active site region of the CHIKV NSP2 protease (PDB: 3TRK)
is delineated in red. The conformation of the active site residues (in
red) was deduced by running SiteHound and MetaPocket web servers
(see ESI†).
This journal is © The Royal Society of Chemistry 2015Cys1290) in its C-terminal region as well as four histidine resi-
dues (His1222, His1228, His1229 and His136), is also a poten-
tial target for the development of peptidomimetic inhibitors.15,22
The HIV/HCV protease inhibitors25–27 (Fig. 3), benchmark
examples of peptidomimetic inhibitors, target the enzymatic
activity of the respective viral proteases. Building on this
knowledge, extensive studies have been performed to develop
peptidomimetic inhibitors that target the DENV NS2B-NS3
(Fig. 5) or CHIKV NSP2 protease (Fig. 4). Because all these
inhibitors share common structural features (Fig. 6), it
prompted us to explore whether HIV/HCV protease inhibitors
could possibly be re-purposed for the inhibition of the replica-
tion of DENV and CHIKV.
In this report, computer-aided drug design (CADD) and
enhanced molecular modeling techniques were used to inves-
tigate whether HIV/HCV protease inhibitors that are already on
the market could have the potential to inhibit the replication of
DENV and CHIKV by exploration of their capacity to bind to the
viral NS2B-NS3 or NSP2 protease, respectively. In parallel, their
biological potency was evaluated in virus-cell-based assays and
was correlated with the in silico results.2. Materials and methods
2.1. Molecular modeling study
The crystal structure of the DENV NS2B-NS3 protease in its
ligand bound conformation (PDB: 3U1I)28 and the CHIKV NSP2
protease (PDB: 3TRK)29 was obtained from the protein data
bank. The closed conformation of the DENV NS2B-NS3 subunit
(PDB: 3U1I)28 was preferred over the open conformation without
ligand (PDB: 2FOM)30 as the protease is presumed to remain in
a closed conformation when bound to an inhibitor. The struc-
tures of the HIV/HCV protease inhibitors that were used in this
study were procured from Chemspider database31 and down-
loaded in MOL2 format. The receptor and ligands were
prepared as mentioned previous by Maharaj et al.32 Subse-
quently, processed ligands were docked in the active site of the
DENV NS2B-NS3 and CHIKV NSP2 protease using AutodockRSC Adv., 2015, 5, 85938–85949 | 85939
Fig. 3 The 2D structures of representative HIV/HCV protease inhibitors that were used in this drug repurposing study. A, B, C, D, E, F, G, H and I
represents, respectively, lopinavir (LPV), nelﬁnavir (NFV), amprenavir (AMP), atazanavir (ATV), indinavir (IDV), ritonavir (RTV), saquinavir (SQV),
telaprevir (TPV) and darunavir (DRV).
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View Article OnlineVina.33 The top docked conformations were generated using
ViewDock34 plugin integrated with Chimera.35
Molecular docking-based binding aﬃnity calculation oen
leads to artifacts. Therefore, further molecular dynamics anal-
ysis was used for further renement. Molecular dynamics-based
MM/GBSA calculation36–40 has proven to be an eﬀective tool toFig. 4 2D representation of the structure (A–D) of some previously-repo
of two CHIKV NSP2 inhibitors as predicted in silico by Rashad et al.22
85940 | RSC Adv., 2015, 5, 85938–85949re-rank protein–inhibitor binding aﬃnity. Therefore, molecular
dynamics based MM/GBSA rescoring36,41–43 was used to precisely
rank the HIV/HCV inhibitors against both target enzymes.
All molecular dynamics simulations were performed using
the GPU version of the PMEMD engine provided with Amber
14 (ref. 44) as described by Bhakat et al.45 The H++ serverrted CHIKV NSP2 inhibitors. A and D represent the chemical structures
This journal is © The Royal Society of Chemistry 2015
Fig. 5 Chemical structures of some previously-reported DENV NS2B-NS3 protease inhibitors. (A) R, R1 are the position of substitutions as
reported by Nitsche et al.;55 (B) one of the anilide reported by Zhou et al.;56 (C) one of the promising NS2B-NS3 inhibitors reported by Yildiz et al.;57
(D) one of the potent DENV NS2B-NS3 inhibitor reported by Ganesh et al.58
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View Article Online(http://biophysics.cs.vt.edu/H++) was used to assign correct
protonation states in case of all the systems prior to system
preparation. In brief, the ligands were parameterized using
GAFF force eld, whereas the protein systems were describedFig. 6 The common peptidomimetic chemical similarity among HIV/HC
inspired the repositioning concept.
This journal is © The Royal Society of Chemistry 2015using FF99SB force eld integrated with Amber 14. The leap
module integrated with Amber 14 was used to add missing
hydrogen atoms and heavy atoms as well as counter ions to
neutralize the systems. All the systems were immersed inV inhibitors, DENV NS2B-NS3 inhibitor/s and CHIKV NSP2 inhibitor/s
RSC Adv., 2015, 5, 85938–85949 | 85941
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View Article Onlinea TIP3P water box so that no atom was within 10 A˚ of any box
edge. Long-range columbic interactions were treated using
particle mesh Ewald (PME) implemented in Amber 14. The
prepared systems were then subjected to diﬀerent stages e.g.
minimizations, heating and equilibration before proceeding
to production runs as described by Bhakat et al.45 Finally,
a 30 ns explicit solvent molecular dynamics simulation was
performed for all the systems using an NPT ensemble with
a target pressure set at 1 bar and constant pressure coupling
of 2 ps.
The molecular dynamics trajectories were analyzed using
PTRAJ and CPPTRAJ modules46 integrated with Amber 14.
Visualization was carried out using VMD47 and Chimera.35
MM/GBSA-based binding energy was calculated using
a singular trajectory approach taking in account 1000 frames
with a regular interval of 30 ps.45 The following set of equations
describes the calculation of binding free energy.
DGbind ¼ Gcomplex  Greceptor  Gligand (1)
DGbind ¼ Egas + Gsol  TDS (2)
Egas ¼ Eint + EVdW + Eele (3)
Gsol ¼ GGB + GSA (4)
GSA ¼ gSASA (5)
The notations of these parameters were described in detail
by Bhakat et al.452.2. DENV and CHIKV cell-based assay
2.2.1. Cells and virus strains. CHIKV Indian Ocean strain
899 (Genbank FJ959103.1) was generously provided by Prof. S.
Gu¨nther (Bernhard Nocht Institute for Tropical Medicine,
Hamburg, Germany). CHIKV was propagated in African green
monkey kidney cells [Vero cells (ATCC CCL-81)]. Vero-B cells
were maintained in cell growth medium composed of
minimum essential medium (MEM Rega-3, Gibco, Belgium)
supplemented with 10% Fetal Bovine Serum (FBS, Integro, The
Netherlands), 1% L-glutamine (Gibco), and 1% sodium bicar-
bonate (Gibco). The antiviral assays were performed in assay
medium, which is the respective cell growth medium supple-
mented with 2% FBS (instead of 10%). All cell cultures were
maintained at 37 C in an atmosphere of 5% CO2 and 95–99%
humidity.
DENV serotype 2 strain New Guinea C (DENV-2 NGC) was
kindly provided by Dr V. Deubel (formerly at Institute Pasteur,
Lyon, France). DENV was propagated in C6/36 mosquito cells
(from Aedes albopictus; ATCC CCL-1660) at 28 C in Leibovitz's
L-15 medium (Life Technologies, cat no. 11415049) supple-
mented with 10% FBS, 1% non-essential amino acids (Life
Technologies, cat no. 11140035), 1% HEPES buﬀer (Life Tech-
nologies, cat no. 15630056) and 1% penicillin (100 U ml1)/
streptomycin (100 mg ml1) solution. Antiviral assays using
DENV were performed on Vero-B cells (obtained from the85942 | RSC Adv., 2015, 5, 85938–85949European Collection of Cell Cultures) using the same assay
medium as was described for CHIKV.
2.2.2. Chikungunya virus CPE reduction assay. CHIKV
cytopathic eﬀect (CPE) reduction assays were performed as
described before (Delang et al., 2014 (ref. 48)). In brief, Vero-B
cells were seeded in 96-well tissue culture plates (Becton Dick-
inson, Aalst, Belgium) at a density of 2.5  104 cells per well in
100 ml assay medium and were allowed to adhere overnight.
Next, a compound dilution series was prepared in the medium
on top of the cells aer which the cultures were infected with
0.01 MOI of CHIKV 899 inoculum in 100 ml assay medium. On
day 5 post-infection (p.i.), the plates were processed using the
MTS/PMS method as described by the manufacturer (Promega,
The Netherlands). The 50% eﬀective concentration (EC50),
which is dened as the concentration of compound that is
required to inhibit viral RNA replication by 50%, was deter-
mined using logarithmic interpolation. Potential cytotoxic/
cytostatic eﬀect of the compound was quantied in unin-
fected cells also by means of the MTS/PMS method. The 50%
cytotoxic concentration (CC50; i.e., the concentration that
reduces the overall metabolic activity of the cells by 50%) was
calculated using logarithmic interpolation. All assay wells were
checked microscopically for minor signs of virus-induced CPE
or alterations of host cell or monolayer morphology that may
have been caused by the compound.
2.2.3. Dengue virus yield reduction assay. Vero-B cells (5 
104) were seeded in 96-well plates. One day later, medium was
replaced by 100 ml assay medium containing 100 CCID50 (50%
cell culture infectious doses) of DENV-2 and incubated for
2 hours, aer which the cell monolayer was washed 3 times with
assay medium to remove non-adsorbed virus. Cells were further
cultivated in 200 ml fresh assay medium containing 2-fold serial
dilutions of the compounds (50–0.20 mg ml1) for 4 days.
Supernatant was harvested and viral RNA load was determined
by real-time quantitative RT-PCR, as previously described
(Kaptein et al., 2010 (ref. 49)). The EC50 value, which is dened
as the compound concentration that is required to inhibit viral
RNA replication by 50%, was determined using logarithmic
interpolation. Potential cytotoxic/cytostatic eﬀects of the
compounds were evaluated in uninfected cells using the
MTS/PMS method similarly as was described for CHIKV.
3. Results and discussions
3.1. Insights from MM/GBSA-based rescoring and the virus-
cell-based assays
From the docking studies, it could be derived that all the
selected HIV/HCV inhibitors are able to physically bind into the
active site of DENV NS2B-NS3 as well as that of the CHIKV NSP2
(Fig. 7). To validate the docking protocol, the peptide-like
inhibitor complexed with DENV NS2B-NS3 protease (PDB:
3U1I28) was extracted in the conguration as it was bound and
was re-docked into the active site of DENV serine protease
(details described in ESI†). Fig. 7 highlights the binding mode
of all HIV/HCV inhibitors inside the active site of DENV
NS2B-NS3 protease and CHIKV NSP2, which also highlights the
preciseness of the docking protocol used in this study.This journal is © The Royal Society of Chemistry 2015
Fig. 7 Superimposed docked conformations of HIV/HCV inhibitors
used in this study within the active site of DENV NS2B-NS3 protease
(PDB: 3U1I) and CHIKV NSP2 (PDB: 3TRK).
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View Article OnlineSubsequently, the docked HIV/HCV protease inhibitors were
subjected to molecular dynamics and post-dynamics
MM/GBSA-based binding free-energy analysis to understand
the binding aﬃnity of these HIV/HCV inhibitors in the active
site of the DENV NS2B-NS3 and CHIKV NSP2 protease. Table 1
lists the MM/GBSA-based scoring prole of the respective
inhibitors. The energies that were derived from diﬀerent
binding free-energy components such as electrostatic, van der
Waals (VdW) contributions were comparatively higher in case of
nelnavir when compared to the other ligands, and this for
both proteases. An interesting observation in all cases was that
contributions coming from VdW components are signicantly
higher than those of electrostatic components, which signies
that VdW interactions are the main driving force behind the
binding of HIV/HCV inhibitors into the active site of the DENV
NS2B-NS3 and CHIKV NSP2 protease.Table 1 MM/GBSA based binding free energy proﬁle in comparison with
studya
Ligand EVdW Eelect Ggas
AMP 29.6529  0.3262{ 0.0619  0.1230{ 29.5911  0
22.4738  0.3892* 1.9473  0.2074* 29.7597  0
ATV 38.0980  0.2978{ 5.2609  0.2709{ 43.3584  0
24.0476  0.6403* 3.7475  0.6056* 36.7568  0
RTV 53.2588  0.2107{ 2.6859  0.1617{ 45.9456  0
23.9486  0.2011* 3.8793  0.3810* 35.8369  0
LPV 28.9049  0.5113{ 8.9503  0.2415{ 30.6537  0
34.0582  0.3940* 4.3948  0.2048* 32.8653  0
DRV 32.5832  0.3492{ 6.5005  0.3255{ 39.0837  0
27.8572  0.4036* 2.7578  0.9063* 37.3605  0
IDV 33.9221  0.5955{ 1.6321  0.9335{ 28.7214  1
22.8304  0.2907* 1.3875  0.2038* 28.8467  0
SQV 38.2987  0.1778{ 15.5666  0.5111{ 25.9531  0
28.7948  0.7207* 3.4743  0.6749* 30.9587  0
NFV 47.7996  0.2034{ 12.1653  0.5720{ 29.6342  0
37.8567  0.2920* 6.4839  0.2841* 30.2874  0
TPV 41.3499  0.2826{ 15.1257  0.0990{ 42.4706  0
26.8658  0.0637* 4.8047  0.6862* 36.7490  0
a { Indicates ligands complexed with DENV NS2B-NS3 (PDB: 3U1I) where
This journal is © The Royal Society of Chemistry 2015To explore whether the in silico results are predictive for
antiviral activity against the respective viruses, the eﬀect of the
HIV/HCV protease inhibitors was evaluated in in vitro virus-
cell-based assays with DENV and CHIKV. As shown in Table
2, most HIV/HCV protease inhibitors did not inhibit the
replication of CHIKV. Only lopinavir and nelnavir showed
a modest antiviral eﬀect (Fig. 8A). None of the compounds
fully inhibited virus-induced cytopathic eﬀects and the anti-
viral activity seems to be associated with an adverse eﬀect on
the host cell (MTS cytotoxicity assay and microscopic evalua-
tion). Likewise, only two out of the nine HIV/HCV protease
inhibitors showed some antiviral activity against DENV-2
(Table 2, Fig. 8B). The antiviral activity of ritonavir is clearly
associated with an adverse eﬀect on the host cell, while the
antiviral eﬀect of nelnavir against DENV-2 was a bit more
pronounced with an EC50 value of 3.5  0.4 mM and a selec-
tivity index (SI) of 4.6 (SI ¼ CC50/EC50). In general, the antiviral
eﬀect of NFV on DENV-2 replication was better compared to
few previously reported DENV inhibitors.15,50,51
It was interesting to observe that nelnavir, the compound
which was found to be the most promising compound in the in
silico study, also showed some antiviral activity against both
viruses in cell culture, (Table 2). It is also necessary to mention
that all HIV/HCV inhibitors displayed a better binding free
energy prole in complex with DENV NS2B/NS3 protease as
compared to CHIKV NSP2, which can be correlated with slightly
better anti-DENV as compared to anti-CHIKV activity. A more
detailed modeling analysis of nelnavir bound in both prote-
ases (see Section 3.2) provided additional support that, even
though the antiviral eﬀect in cell culture was rather modest,
nelnavir showed some interesting features to further explore
its properties as a stepping-stone towards the development of
inhibitors that could inhibit both DENV and CHIKV replication.docking score for all re-proﬁled HIV/HCV inhibitors presented in this
Gsolv DGbind Docking score
.3217{ 6.4800  0.1219{ 23.1111  0.2546{ 7.3{
.5057* 12.1264  0.2073* 12.2947  0.2037* 6.3*
.4630{ 14.3965  0.2768{ 22.9619  0.2981{ 7.2{
.5067* 13.5103  0.3604* 14.2848  0.2057* 6.2*
.3144{ 13.9597  0.1536{ 31.9859  0.2457{ 8.6{
.6037* 13.6207  0.4903 14.2072  0.3803 6.4*
.6095{ 9.5843  0.2877{ 28.2694  0.4378{ 8.4{
.3803* 15.9674  0.2047* 22.4856  0.2710* 6.2*
.5231{ 16.3381  0.3074{ 22.7456  0.2876{ 7.5{
.5063* 18.0774  0.8057* 12.5376  0.7485* 6.6*
.2058{ 12.1607  0.8491{ 23.3925  0.8491{ 7.1{
.7073* 11.8232  0.4063 12.3947  0.1078* 6.6*
.5245{ 25.4092  0.4550{ 28.4561  0.1639{ 7.6{
.7064* 19.4018  0.6539* 12.8673  0.3755* 6.6*
.5895{ 25.9687  0.5257{ 33.9962  0.2118{ 8.9{
.3842* 19.4812  0.4201* 24.8594  0.1047* 6.7*
.3000{ 28.2651  0.1136{ 28.2055  0.2803{ 7.6{
.6402* 14.1308  0.8473* 17.5397  0.2104* 6.2*
as * stands for ligands complexed with CHIKV NSP2 (PDB: 3TRK).
RSC Adv., 2015, 5, 85938–85949 | 85943
Table 2 Antiviral activity of HIV/HCV protease inhibitors against DENV and CHIKV
Protease inhibitors Anti-DENV activity EC50 (mM) CC50 (mM) Anti-CHIKV activity EC50 (mM) CC50 (mM)
Lopinavir 42  20 47  23 32  9 44  12
Nelnavir 3.5  0.4 16  0.4 14  1 22  6
Amprenavir >49 >49 >99 >99
Atazanavir >71 >71 >71 >71
Indinavir >41 >41 >82 >82
Ritonavir 22  4.4 46  27 >69 53
Saquinavir 32  7.7 >37 >75 54
Darunavir >84 >84 >84 >84
Telaprevir 43  10 >50 >50 >50
RSC Advances Paper
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View Article Online3.2. Molecular analysis of the nelnavir–protease
interaction
3.2.1. The nelnavir/DENV NS2B-NS3 interaction. A more
detailed analysis of the interaction of nelnavir with the active
site of the DENV NS2B-NS3 protease delineates a number ofFig. 8 Dose response curves of the antiviral eﬀect (black bars) and th
chikungunya virus CPE reduction assay and (B) lopinavir, nelﬁnavir and r
85944 | RSC Adv., 2015, 5, 85938–85949crucial residues involved in the interaction (Fig. 9). Themajority
of the interactions are hydrophobic and polar type interactions.
Also, a per-residue footprint analysis conrmed that van der
Waals energy is the main driving force for binding, which is
exemplied by the high VdW values in binding free-energy
(Fig. 9C). The position of three catalytic site residues e.g.e cytotoxic eﬀect (white circles) of (A) lopinavir and nelﬁnavir in the
itonavir in the dengue virus yield reduction assay.
This journal is © The Royal Society of Chemistry 2015
Fig. 9 (A) Ligand interactionmap of NFV bound in the active site of the
DENV NS2B-NS3 protease with indication of the diﬀerent interactions
between protein and inhibitor. (B) The putative position of the catalytic
triad and nelﬁnavir (NFV) in the active site of DENV NS2B-NS3
protease. (C) Per-residue footprint of active site residues involved in
the interaction with nelﬁnavir. Highlighting electrostatic and van der
Waals contributions coming from active site residues.
Table 3 Average hydrogen bond distance (A˚) and % occupancy of
interacting active site residues with NFV during simulation time
H-bond interaction Average distance (A˚) % occupancy
Thr83 (OH)/(OH) NFV 2.31 81.3
Met 84 (NH2)/(O52) NFV 3.12 85.2
Met 84 (O)/(NH) NFV 3.08 72.3
Gly 153 (O)/(OH) NFV 2.02 79.3
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View Article OnlineHis51, Asp75 and Ser135 will play a crucial role in the devel-
opment of novel inhibitors using the structural features of NFV
(Fig. 9B). NFV formed two backbone hydrogen bond interac-
tions with Met84 and one with Gly153. It also formed a pi–pi
stacking interaction with Tyr161 and a side chain H bond
interaction with Thr83 (Fig. 9A). A molecular dynamics study
highlights that Met84 and Thr83 formed a stable hydrogen
bond interaction with NFV with higher % occupancy duringThis journal is © The Royal Society of Chemistry 2015simulation time (Table 3). Whereas, the % occupancy of the
hydrogen bond interaction between Gly153 is lower (79.3%) as
compared to the other two residues (Table 3). The lower %
hydrogen bond occupancy in case of Gly153 can be further
conrmed from the fact that the electrostatic contribution
coming from Gly153 is slightly lower (0.15 kcal mol1) when
compared with Thr83. Thus, the backbone H-bond interaction
with Met84, Gly153 and side chain H-bond interaction with
Thr83 played a crucial role in capturing the binding orientation
of NFV inside the active site of the DENV serine protease.
3.2.2. The nelnavir/CHIKV NSP2 interaction. The binding
mode of NFV with the NSP2 of CHIKV puts forward some inter-
esting observations in terms of binding mode as well as residues
that are involved. It was observed that one of the conserved
cysteine residues of the catalytic triad, Cys1290, appears to be
involved in the binding of NFV in the active site. In addition, NFV
interacts with conserved active site residues His1222, Ser1293,
Gly1176 etc. at the C-terminal domain of NSP2 (Fig. 10A). Most
importantly, the formation of a hydrogen bond between His1222
and a carbonyl moiety appears to play an important role in the
stability of NFV inside the active site (Fig. 10A). The majority of
the interactions were polar and hydrophobic in nature, which
correlates with the high value of van der Waals contributions to
the total binding free-energy as well as the high contribution of
VdW forces in the per-residue energy decomposition (Fig. 10B).
The interaction between NFV and the CHIKV NSP2 was found to
be stable during the simulation time with backbone C-a RMSD
and the potential energy of the system was found to be well
converged during the period of simulation (Fig. S1 and S2, ESI†).
To understand the stability of the conserved hydrogen bond
between His1222 and NFV, the H-bond distance and % occu-
pancy between the oxygen atom of the carbonyl group and the
His1222 were monitored during simulation time. From Fig. 10A,
it can be clearly stated that the hydrogen bond between these two
moieties was very stable with a % occupancy of 88.2 and an
average distance of 3.50 A˚, which further points out the role of
His1222 in the stability of NFV inside the active site (Table 4). The
binding conformation of NFV during the simulation time in
respect to conserved cysteine and histidine residues (Fig. 10C)
further gives an insight into the binding theme of NFV that can
help in understanding the development of novel CHIKV inhibi-
tors with the NFV template as starting point.3.3. Conclusive pharmacophore features of nelnavir
The pharmacophore features and hypothesis presented in
Fig. 11 highlights the minimum pharmacophore requirementsRSC Adv., 2015, 5, 85938–85949 | 85945
Fig. 10 (A) Ligand interaction plot showing active site residues of C
terminal CHIKV NSP2 with nelﬁnavir (NFV). (B) Per-residue footprint of
active site residues involved in the interaction with nelﬁnavir (NFV).
Highlighting contributions coming from electrostatic and van der
Waals interactions in case of each residue. (C) The position of catalytic
cysteine residues in the C-terminal domain and His1222 in respective
with nelﬁnavir (NFV).
Table 4 Average hydrogen bond distance and % occupancy between
–NH2 side chain of His1222 and NFV
H-bond interaction Average distance (A˚) % occupancy
His1222 (NH2)/(O49) NFV 3.50 88.2
85946 | RSC Adv., 2015, 5, 85938–85949
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View Article Onlinebased on the structural template of NFV and its interaction with
active site residues of DENV NS2B-NS3 and CHIKV NSP2
protease will help in the design and identication of novel
protease inhibitors that target the DENV NS2B-NS3 and CHIKVFig. 11 (A) and (B) highlights the minimum pharmacophore features of
NFV in bound conformation with DENV NS2B-NS3 protease and
CHIKV NSP2, respectively. The artistic representation of the common
pharmacophore feature of NFV for their DENV/CHIKV protease activity
is described with the arrows. The yellow highlighted region represents
the core area of the peptidomimetic scaﬀold. Green, yellow and white
regions of pharmacophore points represents HP (hydrophobic), HBD
(hydrogen bond donor), HBA (hydrogen bond acceptor) respectively.
This journal is © The Royal Society of Chemistry 2015
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View Article OnlineNSP2. The pharmacophoric features presented in Fig. 11 can be
used as a template for future pharmacophore-based drug
discovery eﬀorts and to screen large commercial databases e.g.
ZINC Pharmer52 etc. to nd novel leads. Not only that: the
combination of structural similarity and minimum pharmaco-
phore features of NFV will be eﬀective in the future to pick new
inhibitors from large pools of chemical compounds to identify
novel small-molecule protease inhibitors against these neglec-
ted tropical diseases.
4. Conclusion
In the present study, we applied a drug re-proling strategy to
explore the antiviral eﬀect of selected HIV/HCV inhibitors
against DENV and CHIKV. The peptidomimetic scaﬀold of
HIV/HCV inhibitors and its structural similarity with previously
reported DENV NS2B-NS3 and CHIKV NSP2 protease inhibitors
inspired us to re-prole HIV/HCV inhibitors against the DENV
NS2B-NS3 and CHIKV NSP2 protease. MM/GBSA-based binding
free energy prole analysis highlighted a better binding of
nelnavir to the DENV NS2B-NS3 and CHIKV NSP2 protease,
which was further validated by a modest antiviral activity of
nelnavir on CHIKV (EC50 ¼ 14  1 mM) and a bit more
pronounced antiviral eﬀect on DENV-2 (EC50 ¼ 3.5  0.4 mM
and SI ¼ 4.6) in virus-cell-based assays. Besides nelnavir,
lopinavir displayed a modest antiviral eﬀect against CHIKV but
none of these compounds fully inhibit virus-induced cytopathic
eﬀects. Ritonavir modestly inhibited DENV-2 but its activity is
clearly associated with an adverse eﬀect on the host cells. From
this study, it can be concluded that NFV has more pronounced
antiviral activity against DENV-2 as compared to CHIKV. The
structural and pharmacophoric features now could be used to
identify novel leads from chemical databases as well as for the
design of novel inhibitors that target both DENV and CHIKV.
This study also gave credibility to the fact that further optimi-
zation of structural and pharmacophore features of nelnavir
may lead to development of multifunctional small-molecule
inhibitor that target both the DENV NS2B-NS3 and CHIKV
NSP2 protease. It is also worth to mention that previous reports
highlighted anti-HCV53 and anti-cancer properties54 of nelna-
vir. Adding to this the antiviral activity against DENV and
CHIKV corroborates that nelnavir has unique properties that
endow it with activity in diﬀerent systems. Thus, future eﬀorts
to understand the structural and pharmacophore features of
nelnavir that are responsible for its diverse activity will be
essential to develop novel multi-functional inhibitors.
Therefore, the binding mode, interaction and pharmaco-
phore features of nelnavir that have been highlighted in this
manuscript will not only act as a stepping stone to develop novel
DENV and CHIKV protease inhibitors, but also may be applied
to identify novel protease inhibitors that target other neglected
viral diseases from large pools of small-molecule inhibitors.
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